Study of 18F-FEC for Positron Emission Tomography-Computed Tomography (PET-CT) Imaging of GBM
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00943462|
Recruitment Status : Withdrawn (No eligible patients could be recruited.)
First Posted : July 22, 2009
Last Update Posted : April 27, 2011
|Condition or disease||Intervention/treatment|
|Astrocytoma, Grade IV Giant Cell Glioblastoma Glioblastoma Multiforme||Radiation: External-beam radiation therapy Drug: Temozolomide|
|Study Type :||Observational|
|Estimated Enrollment :||20 participants|
|Official Title:||Use of PET/CT Imaging With 18F-fluoroethylcholine (FEC) in the Evaluation of Patients Treated With Radiotherapy and Temozolomide Following a Diagnosis of Glioblastoma Multiforme|
|Study Start Date :||June 2009|
|Estimated Primary Completion Date :||June 2011|
|Estimated Study Completion Date :||June 2011|
Glioblastoma Multiforme (GBM)
We will conduct a prospective study on 20 consecutive patients who are seen at the Hôpital Notre‑Dame neuro-oncology clinic for a diagnosis of GBM and who meet our inclusion criteria. We will meet with the eligible patients in order to provide them with a detailed description of the study procedures as well as to have them sign a consent form.
Radiation: External-beam radiation therapy
60 Gy of external beam radiotherapy using a standard technique will be administered in 2‑Gy fractions, for a total of 30 fractions
The chemotherapy will have to be administered in accordance with the protocol used in the CAN-NCIC-CE3 study, which established the current standard for treatment of GBM with the administration of temozolomide as adjuvant therapy at the same time as radiotherapy (clinicaltrials.gov ID NCT00006353).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00943462
|Principal Investigator:||Marie-Andrée Fortin, MD||Centre hospitalier de l'Université de Montréal (CHUM)|